NL
DE
14 February 2020
In patients with rare kidney filter (glomerular) disorders, glomerular injury leads to urinary protein leakage and chronic kidney disease (CKD). Novel therapies to treat glomerular disease or the ensuing progressive CKD have not emerged during the last decade. Thus, there is an unmet need for novel treatment targets, which can be translated into clinically applicable therapy at short term.It is increasingly recognized that paracrine signaling between glomerular endothelial cells and podocytes is crucial to glomerular integrity. Based on preliminary data from their laboratory, Van der Vlag and Nijenhuis hypothesized that nitric oxide (NO) produced by the endothelium activates a podocyte signaling pathway crucial to maintain podocyte viability. This novel paracrine glomerular endothelium-to-podocyte pathway could be therapeutically targeted by repurposing sGC stimulators/activators like Riociguat®.
Johan van der Vlag heads the Nephrology Research Laboratory and, fueled by clinical research questions, focuses on glomerular diseases and (transplantation) immunology. Tom Nijenhuis, internist-nephrologist, specializes in rare kidney disorders.
In patients with rare kidney filter (glomerular) disorders, glomerular injury leads to urinary protein leakage and chronic kidney disease (CKD). Novel therapies to treat glomerular disease or the ensuing progressive CKD have not emerged during the last decade. Thus, there is an unmet need for novel treatment targets, which can be translated into clinically applicable therapy at short term.It is increasingly recognized that paracrine signaling between glomerular endothelial cells and podocytes is crucial to glomerular integrity. Based on preliminary data from their laboratory, Van der Vlag and Nijenhuis hypothesized that nitric oxide (NO) produced by the endothelium activates a podocyte signaling pathway crucial to maintain podocyte viability. This novel paracrine glomerular endothelium-to-podocyte pathway could be therapeutically targeted by repurposing sGC stimulators/activators like Riociguat®.
Johan van der Vlag heads the Nephrology Research Laboratory and, fueled by clinical research questions, focuses on glomerular diseases and (transplantation) immunology. Tom Nijenhuis, internist-nephrologist, specializes in rare kidney disorders.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Grants for heart and kidney research Two awards to Radboudumc in Open Competition ENW-XS
21 July 2022Two researchers from the Radboudumc receive a grant from the NWO within the Open Competition of the Exact and Natural Sciences. They are Thijs Eijsvogels, who studies the heart, and Pieter Leermakers, who studies the kidneys.
read more
ERC Starting Grant awarded to Jeroen de Baaij
17 March 2022 Jeroen de Baaij, kidney researcher the Radboudumc, receives an ERC Starting Grant worth 1.5 million euros. He will use this grant to improve the diagnosis and treatment of severe magnesium deficiencies, which can lead to epileptic seizures and muscle cramps. read more
Academic collaboration agreement between UTwente and Radboudumc
23 November 2021 The group of Biomaterials Science and Technology (BST) of the Faculty of Science and Technology at the TechMed centre of University of Twente has signed a formal academic collaboration agreement with the departments of Nephrology and Physiology at Radboudumc. read more
Senior Kolff Fellowship for Jeroen de Baaij
29 July 2021 Jeroen de Baaij, theme Renal disorders, received a prestigious Senior Kolff grant from the Dutch Kidney Foundation. His project aims to establish dietary approaches against vascular calcification in chronic kidney disease. read more
Magnesium deficiency increases the risk of cardiovascular disease in diabetic patients
21 June 2021 Publication in Diabetes Care. read more
